Molecular Toxicology Lab

Expertise

We bring together molecular pharmacology, toxicology, oncology and systems-level omics to understand disease mechanisms and translate them into safer therapeutics, better biomarkers and targeted interventions — working across cellular and animal models with advanced analytical platforms.

What we study

Core Areas of Expertise

01

Nanotoxicology and Nano–Immune Cell Interactions

The safety and molecular consequences of engineered nanomaterials, particularly those used in biomedical applications, with an emphasis on immune cell interactions, subtoxic effects, and mechanisms that inform regulatory decisions and safer material design.

02

Cancer Mechanisms, Senescence and Therapy Resistance

Tumour recurrence, chemoresistance and senescent cancer cell biology, with the goal of identifying molecular vulnerabilities that improve therapeutic responses across multiple cancer types.

03

Omics-Driven Toxicology and Biomarker Discovery

Using metabolomics and proteomics to map pathway-level changes underlying drug action and toxicity, identifying early detection biomarkers across both in vitro and in vivo models.

04

Neuroinflammation, Neurodegeneration and Aging Biology

How inflammatory and stress-response pathways drive neuronal dysfunction and age-related decline, linking autophagy, mitochondrial quality control, oxidative stress and cellular senescence to disease phenotypes.

05

Metabolic Disease and Mitochondrial Dysfunction

The molecular drivers of diabetes and its complications, including age-dependent mitochondrial abnormalities, and strategies to restore mitochondrial function and enhance cellular resilience.

How we work

Technical Capabilities and Platforms

Cellular and molecular biology

Live-cell and lysate-based luciferase assays, real-time PCR, western blotting, molecular cloning, plasmid preparation

In vivo approaches

Transgenic animal models, animal surgery and in vivo bioluminescent imaging — experience within the team, supported by the College animal facility

Toxicology assays

Cytotoxicity profiling, oxidative stress assays, mitochondrial function assays, trace metal toxicity models

Immunotoxicology

Mechanistic studies in immune cells, including mast cell-focused nanomaterial interactions

Flow cytometry

Phenotyping and functional readouts

Omics technologies

LC–MS metabolomics, NMR metabolomics, proteomic profiling, integrative pathway analyses

Who does what

Faculty Expertise

Dr. Sultan Almudimeegh

Dr. Sultan Almudimeegh

Bridges neuroinflammation and neurodegeneration with interests in cancer, aging biology and nanoparticle toxicology. Current focus: autophagy–senescence links through LRRK2 and senolytics in cancer therapy.

Full profile →

Dr. Nasser B. Alsaleh

Dr. Nasser B. Alsaleh

Investigates the safety of engineered nanomaterials used in biomedical applications and nanomedicine, with a mechanistic focus on nano–immune cell interactions and subtoxic disruption of cellular homeostasis.

Full profile →

Dr. Homood As Sobeai

Dr. Homood As Sobeai

Focuses on discovering novel therapeutics for cancer and understanding how senescent cancer cells contribute to tumour recurrence, alongside the genetic and epigenetic factors shaping cancer progression.

Full profile →

Dr. Mohammed Almutairi

Dr. Mohammed Almutairi

Studies the molecular mechanisms underlying diabetes and neurodegenerative disorders, with a strong emphasis on mitochondrial dysfunction in aging and strategies to improve mitochondrial quality.

Full profile →

Dr. Mohammed Assiri

Dr. Mohammed Assiri

Applies metabolomics and proteomics to uncover mechanisms of drug action, toxicity and disease progression, integrating LC–MS, NMR and proteomic profiling to identify early biomarkers.

Full profile →

Dr. Ali A. Alshamrani

Dr. Ali A. Alshamrani

Targets cancer therapy resistance, dissecting the signalling pathways and survival strategies that let tumours withstand treatment, and identifying vulnerabilities that can re-sensitise cancers to therapy.

Full profile →

How We Collaborate


We welcome collaborations in:

  • Mechanistic toxicology and safety evaluation, including engineered nanomaterials
  • Cancer signalling, senescence and resistance biology
  • Omics-based biomarker discovery for toxicity and disease
  • Neurodegeneration, neuroinflammation and mitochondrial biology
  • Translational projects connecting bench findings to clinical and regulatory needs
MTLAB researchers working at the microscope